Read more
Over the years, India has attained a prominent global position in the manufacture of Generic Drugs. This success can be attributed to its synthetic organic chemistry and chemical engineering strengths, nurtured by the timely policies of the Government of India. However, breakthrough successes in New Drug Discovery have remained elusive, despite the brilliant and sustained efforts of many Indian researchers and Pharma establishments. The Indian National Science Academy thought it appropriate to document India's New Drug Discovery Research (NDDR) journey to date. Gathering contributions from prominent researchers in the Indian Pharma Industry and Academia, this book highlights their efforts, achievements, and the status quo of Indian NDDR.
List of contents
Chapter 1. Traditional Medical System (TMS) for Sustainable Healthcare in India.- Chapter 2. Modern Drug Discovery and Development for TB- The India Narrative.- Chapter 3. Indian Discovery Effort in the Quest of Novel Antibiotics.- Chapter 4. New Drug Discovery and Development in India to Counter Malaria.- Chapter 5. Modern Drug Discovery and Development in the area of Leishmaniasis.- Chapter 6. Modern Drug Discovery and Development: Diabetes and lifestyle disorders Part I - Introduction to Diabetes and Prevalence in India.- Chapter 7. Modern Drug Discovery and Development: Diabetes and lifestyle disorder Part II Type 2 Diabetes Mellitus: Marketed drugs and mechanisms.- Chapter 8. Modern Drug Discovery and Development: Diabetes and lifestyle disorders Part III Anti-diabetes research in India: Contributions from industrial organizations.- Chapter 9. Modern Drug Discovery and Development: Diabetes and lifestyle disorders Part IV Indian Academia Tryst with Cardio-metabolic Drug Discovery and Development.- Chapter 10. Modern drug discovery and development in the area of Cancer: Indian context.- Chapter 11. Biopharmaceutical development in India: recommendations on collaboration and innovation to enable affordable healthcare.- Chapter 12. Regulatory requirements and Quality Standards in India's Clinical Trials Journey.- Chapter 13. Indian Pharma Perspective: New Drug Discovery and Development- Indian Pharmaceutical Industry.
About the author
Dr Madhu Dikshit, a highly respected researcher and former Director of the CSIR-Central Drug Research Institute, Lucknow, India, has made significant contributions to the general area of Molecular Pharmacology with a special interest in redox biology. Dr Dikshit's research has impacted the area of neutrophil biology by enhancing our understanding of e.g. chemotaxis, phagocytosis, apoptosis and also differentiation. Her pioneering work has helped identify the molecular mechanisms involved in the translocation of Nitric Oxide Synthase to the phagosomal compartment and the inflammatory potential of neutrophil extracellular traps. At the CSIR-CDRI, she initiated and led the successful anti-thrombotic drug discovery program, in the context of which two new chemical entities advanced to the pre-clinical stage and one has recently received approval for Phase I clinical trials. Dr Dikshit has published more than 170 papers in peer-reviewed journals, holds eight patents and has supervised more than 30 PhD students. Presently she is the National Chair at Translational Health Sciences & Technology Institute (THSTI), Faridabad and heads its Non-Communicable Disease Program.
